<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742817</url>
  </required_header>
  <id_info>
    <org_study_id>HS-18-00839 - Pilot Study</org_study_id>
    <nct_id>NCT03742817</nct_id>
  </id_info>
  <brief_title>Effects of e-Cigarettes on Perceptions and Behavior</brief_title>
  <official_title>Effects of e-Cigarettes on Perceptions and Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will assess the ways in which e-cigarette product diversity impacts the user
      experience to inform potential regulations by identifying product characteristics that may:
      (1) put young adults at risk for tobacco product use; and (2) facilitate adult smokers
      switching to e-cigarettes. There are three primary objectives to the study: (1) Determine
      which dimensions of e-cigarette product diversity differentially affect product appeal across
      young adult e-cigarette users and middle-age/older adult smokers with an interest in, but no
      significant experience with, e-cigarettes; (2) Determine which dimensions of e-cigarette
      product diversity differentially affect abuse liability in young adult e-cigarette users and
      the ability to resist smoking in adult smokers with an interest in, but no significant
      experience with, e-cigarettes; (3) Determine the affect of product characteristics on
      e-cigarette nicotine delivery profile. For Aim 1, young adult vapers (N=200) and adult
      smokers (N=200) will attend one laboratory session in which they will self-administer
      e-cigarette products varied according to within-subject e-cigarette factors (e.g., flavor,
      pg/vg ratio). For Aim 2, young adults vapers (N=360) and adult smokers (N=360) will
      administer an e-cigarette product and complete behavioral economic tasks that test the
      participant's choice of earning money to delay initiation and continued use of: (1) The
      sampled e-cigarette product (abuse liability; young adult vapers); or (2) Their own brand
      cigarettes (ability to resist smoking; adult current smokers). A pilot study will establish
      device and e-liquid parameters (e.g., nicotine concentration) to be used for all aims.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study recruitment temporarily suspended due to COVID-19 pandemic.
  </why_stopped>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Appeal</measure>
    <time_frame>1 hour</time_frame>
    <description>Self-report measures of product appeal will be completed following the e-cigarette administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Affect Negative Affect Schedule</measure>
    <time_frame>4 hours</time_frame>
    <description>The 10-item Positive Affect Negative Affect Schedule (PANAS-SF) will be used to measure positive and negative affect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire of Vaping Urges</measure>
    <time_frame>4 hours</time_frame>
    <description>10-item Brief Questionnaire of Vaping Urges will assess desire, intention, urge and need to vape e-cigarettes.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Electronic Cigarettes</condition>
  <arm_group>
    <arm_group_label>Sweet-Flavor 4.5% Nicotine (Salt)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sweet-Flavor 0 mg/mL Nicotine (Free-Base)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sweet-Flavor 6 mg/mL Nicotine (Free-Base)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual e-Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>e-Cigarette</intervention_name>
    <description>Participants will self-administer an experimenter-provided e-cigarette.</description>
    <arm_group_label>Sweet-Flavor 0 mg/mL Nicotine (Free-Base)</arm_group_label>
    <arm_group_label>Sweet-Flavor 4.5% Nicotine (Salt)</arm_group_label>
    <arm_group_label>Sweet-Flavor 6 mg/mL Nicotine (Free-Base)</arm_group_label>
    <arm_group_label>Usual e-Cigarette</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Vapers

          1. E-cigarette use &gt;3 day/week for &gt;2 months

          2. Report regularly using e-cigarette products with nicotine

          3. Positive cotinine test via NicAlert test strip

        Smokers

          1. Daily cigarette smoking for â‰¥ 2 years

          2. Currently smoke &gt; 4 cig/day

          3. Interest in trying an e-cigarette or current use of e-cigarettes

        Exclusion Criteria:

        Vapers

          1. Pregnancy/breastfeeding

          2. Desire to immediately reduce e-cigarette use

        Smokers

          1. Breath CO &lt; 9ppm at intake

          2. Pregnancy / breastfeeding

          3. Current daily use of other combustible tobacco products (e.g., cigars)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam M Leventhal, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Adam Leventhal</investigator_full_name>
    <investigator_title>Professor of Preventive Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

